Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice | Zendy

Yvonne Dempsie | Zendy; Ian Morecroft | Zendy; David Welsh | Zendy; Neil MacRitchie | Zendy; Nigel Herold | Zendy; Lynn Loughlin | Zendy; Margaret Nilsen | Zendy; Andrew J. Peacock | Zendy; Anthony J. Harmar | Zendy; Michael Bäder | Zendy; Margaret R. MacLean | Zendy

Open Access

Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice

Author(s) -

Yvonne Dempsie,

Ian Morecroft,

David Welsh,

Neil MacRitchie,

Nigel Herold,

Lynn Loughlin,

Margaret Nilsen,

Andrew J. Peacock,

Anthony J. Harmar,

Michael Bäder,

Margaret R. MacLean

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.767558

Subject(s) - dexfenfluramine , medicine , serotonin , pulmonary hypertension , hypoxia (environmental) , endocrinology , serotonin transporter , pharmacology , fenfluramine , receptor , chemistry , organic chemistry , oxygen

The incidence of pulmonary arterial hypertension secondary to the use of indirect serotinergic agonists such as aminorex and dexfenfluramine led to the "serotonin hypothesis" of pulmonary arterial hypertension; however, the role of serotonin in dexfenfluramine-induced pulmonary arterial hypertension remains controversial. Here, we used novel transgenic mice lacking peripheral serotonin (deficient in tryptophan hydroxylase-1; Tph1(-/-) mice) or overexpressing the gene for the human serotonin transporter (SERT; SERT(+) mice) to investigate this further.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research